RAF1 Knockout HAP1 Cell Line

The choice depends on whether you are studying RAF1's role as a central MAP3K in the RAS-RAF-MEK-ERK cascade or its emerging functions in apoptosis regulation and Noonan syndrome biology. The Knockout line is the standard tool for asking whether RAF1 is required for these processes — RAF1 (along with BRAF and ARAF) phosphorylates and activates MEK1/2 downstream of activated RAS. Overexpression is useful for studying RAF1 gain-of-function or for testing Noonan syndrome-associated gain-of-function mutations. Important consideration: RAF1, BRAF, and ARAF share substantial functional overlap. Single RAF1 knockout in HAP1 may show modest MAPK phenotypes if BRAF compensates, but RAF1 has unique apoptotic functions through interaction with ASK1, MST2, and mitochondrial substrates that are not redundant with BRAF. RAF1 mutations cause Noonan syndrome and LEOPARD syndrome — disease variant rescue enables genotype-function correlation studies. Rescue with wild-type, kinase-dead (K375M), or Noonan-associated activating mutant RAF1 enables comprehensive structure-function studies. The knockout is valuable as a specificity control for RAF inhibitors (sorafenib, regorafenib, RAF dimer breakers).

Primary applications: • MAPK pathway analysis: phospho-MEK1/2 (S217/S221) and phospho-ERK1/2 (T202/Y204) Western blot to assess RAF1-dependent MAPK signaling. • Apoptosis regulation: studies of RAF1's reported anti-apoptotic functions through ASK1/MST2 inhibition, distinct from BRAF. • Noonan syndrome modeling: rescue with disease-associated activating RAF1 mutations (e.g., S257L, P261S) for genotype-function studies of RASopathies. • RAF inhibitor specificity: critical genetic control for sorafenib, regorafenib, and RAF dimer breakers in cancer drug development. EDITGENE recommends this model for researchers investigating MAPK signaling, RASopathy mechanisms, and RAF inhibitor pharmacology.

Yes. RAF1 rescue experiments are well-established for MAPK pathway research: • Construct design: use a codon-modified RAF1 sequence with a small C-terminal tag (FLAG, HA). RAF1 has N-terminal regulatory region (CR1 with RBD, CR2 with phospho-serine 14-3-3 sites), and C-terminal kinase domain — preserve all elements. • Kinase-dead rescue: the K375M mutation in the ATP-binding lysine abolishes catalytic activity and is the standard specificity control for distinguishing kinase from scaffolding functions. • Noonan syndrome rescue: activating mutations (S257L, P261S, S259F) enable disease genotype-function studies of RASopathy mechanism. • Phospho-regulatory rescue: S259A (release from 14-3-3 autoinhibition) generates partial gain-of-function RAF1 useful for distinguishing activation steps. • Functional readout: rescue should restore RAS-induced MEK/ERK activation and downstream gene expression. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.